COX19

Across TCGA pan-cancer cohorts, COX19 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of COX19’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where COX19 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types COX19 is over-expressed in tumor, although a few such as CCRCC and PDAC show the opposite, repressed pattern.

CCRCC, PDAC, and HNSC are the cancer types where COX19 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in COX19 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	III,IV	−0.777	<.001	12	view →
PDAC	Male	All	−0.495	<.001	8	view →
HNSC	Male	II,III,IV	−0.384	<.001	8	view →
LSCC	Female	All	−0.364	<.001	8	view →
COAD	Female	II,III,IV	−0.166	.010	4	view →
LUAD	Male	All	+0.109	.009	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

COX19–CCRCC

Open the CCRCC breakdown →